Search

Abstract Background Techniques in endovascular therapy have evolved to offer a promising alternative to medical therapy alone for Type B aortic dissections (TBADs). Aim The aim of this meta-analysis was to compare mortality and overall complications between thoracic endovascular aortic repair (TEVAR) and best medical therapy (BMT) in patients with TBADs. Methods We included randomized control trials and prospective or retrospective cohort studies that compared TEVAR and BMT for the treatment of type B aortic dissection. Multiple electronic databases were searched. Results Thirty-two cohort studies including 150,836 patients were included. TEVAR was associated with a significantly lower 30-day mortality rate than BMT (RR = 0.79, CI = 0.63, 0.99, P = 0.04), notably in patients ≥ 65 years of age (RR = 0.78, CI = 0.64, 0.95, P = 0.01). The TEVAR group had a significantly prolonged hospital stay (MD = 3.42, CI = 1.69, 5.13, P = 0.0001) and ICU stay (MD = 3.18, CI = 1.48, 4.89, P = 0.0003) compared to the BMT. BMT was associated with increased stroke risk (RR = 1.52, CI = 1.29, 1.79, P

Abstract Background Aspirin has been proven to be effective in preventing preeclampsia (PE) in singleton pregnancies. However, the use of aspirin for women with twin pregnancies is still debatable. The purpose of our meta‐analysis is to evaluate the effectiveness of aspirin for preventing preeclampsia in twin pregnancies. Methods We searched the following databases: PubMed, Scopus, Cochrane Library and Web of Science. Twelve studies were included in the meta‐analysis. The quality assessment and ROB were executed using NOS and ROB 2 respectively. RevMan software 5.4 was used for performing the analysis. Results The pooled analysis showed no significant difference between the administration of aspirin and the control group in decreased incidence of PE, hypertensive disorders, IUGR or twin‐to‐twin discordance (RR = 0.73, CI = 0.43–1.24, p = 0.24), (RR = 0.60, CI = 0.34–1.07, p = 0.08), (RR = 0.90, CI = 0.45–1.82, p = 0.77) and (RR = 1.76, CI = 0.83–3.73, p = 0.14), respectively. However, the pooled analysis showed a statistically significant association between aspirin and decreased incidence of preterm birth (PTB) (RR = 0.58, CI = 0.39–0.86, p = 0.006). Subgroup analysis of the dose revealed a significant association between 100 mg of aspirin and decreased PE incidence compared with the control group (RR = 0.44, CI = 0.23–0.84, p = 0.01). Conclusion The overall analysis showed no significant role of Aspirin in reducing the incidence of PE. The dose subgroup analysis revealed that only 100 mg of Aspirin is effective in decreasing PE. Future multicentre randomized control trials are warranted to give us conclusive results.

Abstract Background Etrolizumab is a promising drug for treating moderate to severe ulcerative colitis. Aim The aim of this study was to assess the efficacy and safety of etrolizumab for induction and maintenance of remission in moderate to severe ulcerative colitis. Methods We searched the following databases: PUBMED, Web of Science, OVID, and SCOPUS from inception to January 15. Inclusion criteria were any phase 2 and 3 clinical trials that compared etrolizumab with a placebo in treating moderate to severe ulcerative colitis, excluding case reports, animal studies, phase 1 trials, and conference abstracts due to duplication. We used RevMan software (5.4) for the meta‐analysis. Results Five clinical trials were included in our meta‐analysis. The total number of patients included in the study is 1248 patients, 860 patients in the etrolizumab group and 388 patients in the placebo group. In the induction phase, the pooled analyses showed a statistically significant association between etrolizumab and increased clinical remission, and endoscopic remission compared with placebo (risk ratio [RR] = 2.66, 95% confidence interval [CI] = 1.69–4.19, p

Background and aim: Recent studies reported a significant association between enteric dysmotility and GnRH antibodies, other studies reported no significant association. Therefore, we aimed to perform a meta-analysis to investigate and clarify the exact association between enteric dysmotility and GnRH antibodies. Methods: PubMed, Web of Science, and Scopus databases were searched. The inclusion criteria were any randomized control trials or observational studies that reported the level or prevalence of GnRH IgM or GnRH IgG antibodies in patients with enteric dysmotility matched with healthy controls. Exclusion criteria: Case reports, case series, reviews, editorials, and animal studies. RevMan software 5.4 was used to perform the meta-analysis. Results: After search of the literature, 4 studies were included in the meta-analysis with a total number of 469 individuals included in the study. The pooled analysis showed a statistically significant association between enteric dysmotility and increased prevalence of GnRH IgM antibodies compared with controls (RR ​= ​4.47, 95% CI ​= ​1.17 to 17.06, p-value ​= ​0.03). Contrarily, no statistically significant association between enteric dysmotility and the levels of IgM antibodies as well as the prevalence of IgG antibodies was found compared with controls, (MD ​= ​0.92, 95% CI ​= ​-1.01 to 2.86, p-value ​= ​0.35) and (RR ​= ​1.84, 95% CI ​= ​0.09 to 35.86, p-value ​= ​0.69), respectively. Conclusion: Our study detected a significant association between intestinal dysmotility and high prevalence of GnRH IgM antibodies when matched with controls. Conversely, we found no statistically significant association between enteric dysmotility and IgG antibodies. Further research is warranted to support our results and clarify the exact association between enteric dysmotility and GnRH antibodies.

Abstract Introduction The Mycobacterium abscessus complex is a nontuberculous mycobacteria species that is pervasive in soil and water. Various medical equipment malfunctions, infected surfaces, and patient transmission are potential causes of Mycobacterium abscessus infection in the hospital environment. These cases have an annual prevalence that ranges from 1.4 to 6.6 per 100,000 infections, mainly increasing. Case presentation We present the case of a 23-year-old American female patient who presented to the emergency room with significant abdominal pain between low pelvic sutures and the umbilicus. She reported abdominal pain, pruritus, and boils on her back preventing her from standing upright. The symptoms occurred in the liposuction area after cosmetic surgery in the Dominican Republic. The clinical, radiological, and cultural findings helped diagnose Mycobacterium abscessus infection. We conducted a mini literature review on the published reports of Mycobacterium abscessus. Conclusion Mycobacterium abscessus infection may occur due to surgical procedures abroad. Measures are required to combat Mycobacterium abscessus and reduce its prevalence in hospital settings.

Several reports showed the likelihood of a relationship between COVID-19 infection and the onset and prognosis of diabetes mellitus (DM) of all types. A 73-year-old female patient who presented to the clinic with respiratory symptoms and was tested positive for COVID-19 and treated for the next three days. Despite having neither a known history of hyperglycemia nor a family history of diabetes, she was unconscious and suffering from polyuria and polydipsia when she was brought to the emergency department. Once her condition was successfully stabilized, she was sent home with COVID-19 medications and oral anti-diabetic therapy. After subsequent viral recovery and continued anti-diabetic medication, the patient was monitored for the following seven months. DM might be linked to the SARS-CoV-2 infection. Further research is necessary to prove a relationship between COVID-19 and newly-onset diabetes.

Background and aimRecent studies evaluated the role of vamorolone in treating Duchenne muscular dystrophy (DMD), so we aimed in our Meta-analysis to assess the efficacy of vamorolone in comparison with placebo and corticosteroids for treating DMD patients.MethodsWe searched PubMed, Web of Science, Scopus, and Cochrane library databases. We included any randomized control trials and controlled observational studies that investigated the role of vamorolone in treating DMD patients. We used RevMan software, version 5.4. to perform our meta-analysis.ResultsAfter a search of the literature, 4 studies were included in the meta-analysis; the total number of patients included in the study is 277 patients, 125 patients in the vamorolone group, 106 in the glucocorticoids group, and 46 in placebo (steroid naïve) group. The pooled analysis showed a statistically significant association between the vamorolone group and increased TTSTAND velocity, TTRW velocity and TTCLIMB velocity compared with the placebo group (MD = 0.04, 95% CI = 0.02–0.07, p = 0.002), (MD = 0.24, 95% CI = 0.11–0.37, p = 0.0003), and (MD = 0.06, 95% CI = 0.05–0.06, p < 0.00001), respectively. Also, the analysis showed a statistically significant association between vamorolone and increased TTRW velocity and increased Height percentile for age compared with the glucocorticoid group (MD = −0.14, 95% CI = −0.26 to −0.01, p = 0.03) and (MD = 17.82, 95% CI = 3.89–31.75, p = 0.01), respectively.ConclusionOur study revealed a significant association between vamorolone and increased TTSTAND velocity, TTRW velocity, and TTCLIMB velocity compared with the placebo (steroid naïve), also showed a statistically significant association between increased TTRW velocity and increased Height percentile for age compared with the glucocorticoid that enhances the privilege of vamorolone over glucocorticoid in treating DMD patients. More multicenter randomized studies are needed to support our results.